Physician profile
Robert C Lee
NPI 1497830293
$2,346.32
in general payments reported to CMS, 2019-2025
23 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.88 · 2021: $112 · 2022: $458 · 2023: $322 · 2024: $432 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,762.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $927.85 | 2021-2025 | Nucala, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $188.02 | 2020-2025 | Winrevair, Prevymis, Zerbaxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.20 | 2021-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $145.43 | 2022-2023 | Fasenra |
| Amgen INC. | $129.78 | 2022 | |
| Shionogi INC | $118.60 | 2025 | Fetroja |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.31 | 2022-2023 | Lifevest |
| Intuitive Surgical, INC. | $89.18 | 2024 | |
| Nxstage Medical, INC. | $77.99 | 2025 | Nxstage System One |
| Potrero Medical, INC. | $77.01 | 2023 | |
| Mindray Ds USA, INC. | $44.81 | 2024 | Te7 Max, Te X |
| Mylan Specialty L.P. | $38.15 | 2024 | Yupelri |
| Insmed, INC. | $37.07 | 2025 | Arikayce, Brinsupri |
| Advanced Respiratory, INC | $32.11 | 2021 | |
| Medtronic, INC. | $26.19 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $24.99 | 2021-2022 | |
| Viatris Specialty LLC | $20.90 | 2025 | Yupelri |
| Abiomed | $20.07 | 2024 | Impella |
| Philips North America LLC | $20.00 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.35 | 2025 | Glassia |
| Inquis Medical, INC. | $18.13 | 2024 | |
| Grifols USA, LLC | $15.62 | 2022 | |
| Mallinckrodt Hospital Products INC. | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.